Treatment of Helicobacter Pylori Infection in Patients with Chronic Kidney Disease on Dialysis

Recommended Treatment Regimens

The American Gastroenterological Association recommends a 14-day quadruple therapy with bismuth for the treatment of Helicobacter pylori infection in patients with chronic kidney disease on dialysis, as it offers the highest efficacy in areas with high antibiotic resistance and is safe in patients with compromised renal function 1
The treatment regimen includes an inhibitor of proton pump (twice a day), bismuto (four times a day), metronidazol (500 mg three or four times a day, with dose adjustment according to renal function), and tetracycline (500 mg four times a day) 1

The dose of metronidazol should be reduced by 50% in patients on dialysis, as recommended by the Gut Microbes journal 2
Tetracycline can be used as an alternative to amoxicillin in patients allergic to penicillin, with no significant dose adjustment required in patients on dialysis 2
Clarithromycin does not require significant dose adjustment in patients on dialysis, according to the Gastroenterology journal 1

The treatment should be scheduled preferably after the dialysis session to avoid premature elimination of the drug, as suggested by the Praxis Medical Insights journal 3
Potential drug interactions, especially with drugs metabolized by CYP3A4, should be monitored, as recommended by the Gastroenterology journal 1
Concomitant use of nephrotoxic agents during treatment should be avoided, according to the Praxis Medical Insights journal 4

Eradication should be verified 4-8 weeks after completing treatment using a stool antigen test, urea breath test, or endoscopy with biopsy, as recommended by the Gastroenterology journal 1
Rescue therapies based on bismuth should be considered if initial treatment fails, according to the Gastroenterology journal 1
Renal function should be monitored during treatment, as suggested by the Praxis Medical Insights journal 3

The use of non-steroidal anti-inflammatory drugs (NSAIDs) during and after treatment should be avoided, as they increase the risk of peptic ulcer bleeding in patients with chronic kidney disease, according to the Praxis Medical Insights journal 4
In patients with cirrhosis, protease inhibitors such as glecaprevir-pibrentasvir should be avoided due to the risk of hepatotoxicity, as recommended by the Gastroenterology journal 1
In case of penicillin allergy, amoxicillin can be replaced with tetracycline, according to the Gut Microbes journal 2